Viral Disease Management

Viral disease management

New opportunities in viral disease management with sustained drug delivery

The management and treatment of viral diseases like HIV has long been a challenge for both patients and the pharmaceutical industry. This is why our experts are working closer than ever with our pharmaceutical partners to extend the duration of therapies and enable the potential for easier access to treatment with our TheraPEA™ sustained drug delivery solution.

We work with partners worldwide across the continuum of healthcare to enable unique drug delivery solutions for viral disease that bring progress to life for patients

15+ Years

Of experience in sustained drug delivery applications.

30+ Years

Of experience working with the world’s leading pharmaceutical companies.

150+ Years

Of combined scientific discovery and heritage as part of dsm-firmenich.

Creating next-generation therapies with TheraPEA™

Our TheraPEA™ polyester amide platform is unlocking entirely new therapeutic opportunities for the pharmaceutical industry through its ability to achieve multi-month, controlled drug release.

This highly tunable biomaterial has a zero-order degradation profile and good correlation in-vitro and in-vivo up to 180 days. Furthermore, the unique chemistry of TheraPEA™ changes the game even further through its compatibility with a wide range of challenging Active Pharmaceutical Ingredients.

By developing customized drug delivery solutions with our partners in this way, we can enable longer duration therapies for patients with the potential to increase therapy adherence – and allow for improved clinical outcomes, better healthcare economics and significantly less medical waste.

Learn more about our drug delivery solutions.

The doctor holding a syringe with Covid-19 vaccines in glass bottle. Covid-19 corona virus treatment concept.

Discover our drug delivery solutions for viral disease management

Our drug delivery solutions have huge potential for various viral diseases, including hepatitis. They are especially promising in HIV pre-exposure prophylaxis and management.

With our TheraPEA™ platform, we enable our pharmaceutical partners to create implantable and long-acting injectable therapies that give patients better access to the treatments they need – both in the United States and beyond (for example, in sub-Saharan Africa).

Extending the therapy duration can also increase patient adherence – which of course is essential for ensuring the effectiveness of the prophylaxis (PreP).